C-PALSY Archives

Cerebral Palsy List

C-PALSY@LISTSERV.ICORS.ORG

Options: Use Forum View

Use Monospaced Font
Show Text Part by Default
Show All Mail Headers

Message: [<< First] [< Prev] [Next >] [Last >>]
Topic: [<< First] [< Prev] [Next >] [Last >>]
Author: [<< First] [< Prev] [Next >] [Last >>]

Print Reply
Subject:
From:
Meir Weiss <[log in to unmask]>
Reply To:
Cerebral Palsy List <[log in to unmask]>
Date:
Mon, 19 Jun 2006 15:29:51 -0400
Content-Type:
text/plain
Parts/Attachments:
text/plain (49 lines)
Jun 19, 1:04 PM EDT

Seizure Leads Novartis to Recall Patches 

 U.S. Video 

WASHINGTON (AP) -- A child suffered a seizure after chewing on a
cough-suppressing vapor patch, leading Novartis AG to recall the patches Monday.
The Swiss drug company warned consumers to stop using its Triaminic Vapor
Patches immediately.

The recalled patches include both the mentholated cherry and menthol scented
versions sold by Novartis Consumer Health. They should be discarded or returned
to the place of purchase for a full refund, the company said.

The patches contain camphor, eucalyptus oil and menthol and are meant to be
applied to the chest or throat of children as young as 2 to allow vapors to
reach the nose and mouth. The company said the placement of the patches can
allow children to remove and place them in their mouths.

Ingesting camphor or eucalyptus oils can cause a burning sensation in the mouth,
headache, nausea, vomiting or seizure. In the single reported case of a seizure,
the child recovered that same day, the company said.
 
Other complaints associated with the patches include reports of blistering,
bruising, scarring, hyperactivity and depigmentation, the company said.

Parents and other consumers with questions should contact Novartis at (800)
452-0051 or visit http://www.triaminic.com , the company said.

Any adverse reactions associated with the patches should be reported to the Food
and Drug Administration through the agency's MedWatch program, either online at
http://www.fda.gov/MedWatch/report.htm or by telephone at (800) FDA-1088.

Novartis said it has sold more than 50 million Triaminic Vapor Patches since
introducing them in 2000. They are sold through pharmacies and retail stores.

C 2006 The Associated Press. All rights reserved. This material may not be
published, broadcast, rewritten or redistributed. Learn more about our Privacy
Policy.

 Purchase this AP story for reprint.

-----------------------

To change your mail settings or leave the C-PALSY list, go here:

http://listserv.icors.org/SCRIPTS/WA-ICORS.EXE?SUBED1=c-palsy

ATOM RSS1 RSS2